DARRIN UECKER - 11 Sep 2025 Form 4 Insider Report for PULSE BIOSCIENCES, INC. (PLSE)

Role
Chief Technology Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
11 Sep 2025
Transactions value $
-$821,750
Form type
4
Filing time
15 Sep 2025, 21:09:38 UTC
Previous filing
16 Jun 2025
Next filing
18 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
UECKER DARRIN Chief Technology Officer, Director C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD /s/ Kenneth B. Stratton, as Attorney-in-Fact 15 Sep 2025 0001276311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLSE Common Stock Options Exercise $100,000 +25,000 +20.3% $4.00 147,872 11 Sep 2025 Direct F1
transaction PLSE Common Stock Sale -$369,500 -25,000 -16.9% $14.78 122,872 11 Sep 2025 Direct F1, F2
transaction PLSE Common Stock Options Exercise $100,000 +25,000 +20.3% $4.00 147,872 12 Sep 2025 Direct F1
transaction PLSE Common Stock Sale -$358,000 -25,000 -16.9% $14.32 122,872 12 Sep 2025 Direct F1, F3
transaction PLSE Common Stock Options Exercise $100,000 +25,000 +20.3% $4.00 147,872 15 Sep 2025 Direct F1
transaction PLSE Common Stock Sale -$394,250 -25,000 -16.9% $15.77 122,872 15 Sep 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Options Exercise $0 -25,000 -13.8% $0.000000 156,534 11 Sep 2025 Common Stock 25,000 $4.00 Direct F1, F5
transaction PLSE Stock Option (right to buy) Options Exercise $0 -25,000 -16% $0.000000 131,534 12 Sep 2025 Common Stock 25,000 $4.00 Direct F1, F5
transaction PLSE Stock Option (right to buy) Options Exercise $0 -25,000 -19% $0.000000 106,534 15 Sep 2025 Common Stock 25,000 $4.00 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.
F2 The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $14.41 to $15.14 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.
F3 The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $13.80 to $14.76 per share.
F4 The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.18 to $17.20 per share.
F5 Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015.